These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1263 related articles for article (PubMed ID: 19698901)
21. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Perry R; Cassagnol M Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900 [TBL] [Abstract][Full Text] [Related]
22. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624 [TBL] [Abstract][Full Text] [Related]
23. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. Kornstein SG; Clayton AH; Soares CN; Padmanabhan SK; Guico-Pabia CJ J Clin Psychopharmacol; 2010 Jun; 30(3):294-9. PubMed ID: 20473066 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642 [TBL] [Abstract][Full Text] [Related]
25. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert JE; Franznick DA; Hollander SB; Fava M J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591 [TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. Liebowitz MR; Yeung PP; Entsuah R J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559 [TBL] [Abstract][Full Text] [Related]
27. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958 [TBL] [Abstract][Full Text] [Related]
28. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. Griebel G; Beeské S; Stahl SM J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246 [TBL] [Abstract][Full Text] [Related]
29. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411 [TBL] [Abstract][Full Text] [Related]
30. Paroxetine versus placebo: a double-blind comparison in depressed patients. Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR; J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817 [TBL] [Abstract][Full Text] [Related]
32. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
34. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. Simon JS; Aguiar LM; Kunz NR; Lei D J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Germino FW Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484 [TBL] [Abstract][Full Text] [Related]
36. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Tourian K; Wang Y; Ii Y Int Clin Psychopharmacol; 2013 Jul; 28(4):206-13. PubMed ID: 23587982 [TBL] [Abstract][Full Text] [Related]
37. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410 [TBL] [Abstract][Full Text] [Related]
38. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941 [TBL] [Abstract][Full Text] [Related]
39. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M; J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369 [TBL] [Abstract][Full Text] [Related]
40. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]